Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
24 hedge funds and large institutions have $6.37M invested in Regulus Therapeutics in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 5 closing their positions.
15% more capital invested
Capital invested by funds: $5.55M → $6.37M (+$819K)
2.82% less ownership
Funds ownership: 37% → 34.19% (-2.8%)
14% less funds holding
Funds holding: 28 → 24 (-4)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$268K |
| 2 |
Rockefeller Capital Management
New York
|
+$71.7K |
| 3 |
Renaissance Technologies
New York
|
+$48.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$755K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
-$14.1K |
| 3 |
VF
Virtu Financial
New York
|
-$12K |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$10K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$5.97K |
RGLS Hedge Fund Activity: Q4 2019 in Review
24 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q4 2019, worth a combined $6.37M — up 15% from $5.55M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of RGLS and 1 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was CVI Holdings, opening a new position worth an estimated $268K. The largest seller was EcoR1 Capital, exiting entirely with an estimated $755K sold.
- 24 institutional investors held Regulus Therapeutics (RGLS) as of Q4 2019, down from 28 in Q3 2019.
- Funds reported $6.37M of Regulus Therapeutics stock for Q4 2019, up 15% quarter-over-quarter.
- 1 fund opened new Regulus Therapeutics positions in Q4 2019 and 5 closed out, a net change of -4 holders.
- The largest Regulus Therapeutics buyer in Q4 2019 was CVI Holdings, an estimated $268K added.
- The largest Regulus Therapeutics seller in Q4 2019 was EcoR1 Capital, an estimated $755K sold.
Based on aggregated 13F filings for Q4 2019.